Thomas A. Fleisher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas A. Fleisher has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- João Bosco Oliveira
Hospital Israelita Albert Einstein São Paulo SP Brazil Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
3 shared publications Agustin A. Gil Silva
Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland, USA
2 shared publications- Hye Sun Kuehn
Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, USA
2 shared publications - Jennifer Stoddard
Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland, USA
2 shared publications - Julie E. Niemela
Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland, USA
2 shared publications - Luigi Daniele Notarangelo
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
2 shared publications
Latest Publications
- Open Access
- 22 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (24)
IKAROS regulates human T cell phenotype at a thymic and postthymic level
The transcription factor IKAROS, encoded by IKZF1 , is crucial for lymphocyte development and differentiation. Germline heterozygous IKZF1 mutations cause B cell immunodeficiency, but also affect T cells. Patients with IKZF1 haploinsufficiency (HI) or dimerization-defective (DD) variants show reduced naive and increased memory T cells, while dominant-negative (DN) mutations result in the opposite phenotype. Gain-of-function patients display variable patterns. To investigate IKAROS’s role in shaping the human naive/memory T cell phenotype, we performed IKAROS immunomodulation and knockdown experiments and analyzed early T cell development in an artificial thymic organoid (ATO) system using CD34 + cells from patients with representative IKZF1 variants. IKAROS inhibition by lenalidomide or silencing by small hairpin RNA directly altered expression of HNRNPLL, the master regulator of CD45 isoform splicing that defines CD45RA + /naive and CD45RO + /memory phenotypes. In the ATO system, IKAROS-DN precursor cells were blocked at the CD4 – CD8 – /double-negative stage and retained a CD45RA + phenotype, whereas IKAROS-HI cells inefficiently reached the CD4 + CD8 + /double-positive stage and partially transitioned from CD45RA to CD45RO. Analysis of public gene expression data showed high HNRNPLL expression in double-positive thymic cells, beyond the stages affected by IKZF1 DN and HI mutations. Collectively, these findings indicate that IKAROS regulates early and late T cell development by mechanisms, including HNRNPLL modulation.
- 22 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (24)
Open AccessIKAROS regulates human T cell phenotype at a thymic and postthymic level
The transcription factor IKAROS, encoded by IKZF1 , is crucial for lymphocyte development and differentiation. Germline heterozygous IKZF1 mutations cause B cell immunodeficiency, but also affect T cells. Patients with IKZF1 haploinsufficiency (HI) or dimerization-defective (DD) variants show reduced naive and increased memory T cells, while dominant-negative (DN) mutations result in the opposite phenotype. Gain-of-function patients display variable patterns. To investigate IKAROS’s role in shaping the human naive/memory T cell phenotype, we performed IKAROS immunomodulation and knockdown experiments and analyzed early T cell development in an artificial thymic organoid (ATO) system using CD34 + cells from patients with representative IKZF1 variants. IKAROS inhibition by lenalidomide or silencing by small hairpin RNA directly altered expression of HNRNPLL, the master regulator of CD45 isoform splicing that defines CD45RA + /naive and CD45RO + /memory phenotypes. In the ATO system, IKAROS-DN precursor cells were blocked at the CD4 – CD8 – /double-negative stage and retained a CD45RA + phenotype, whereas IKAROS-HI cells inefficiently reached the CD4 + CD8 + /double-positive stage and partially transitioned from CD45RA to CD45RO. Analysis of public gene expression data showed high HNRNPLL expression in double-positive thymic cells, beyond the stages affected by IKZF1 DN and HI mutations. Collectively, these findings indicate that IKAROS regulates early and late T cell development by mechanisms, including HNRNPLL modulation.
- Open Access
- 1 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (3)
Disease-associated AIOLOS variants lead to immune deficiency/dysregulation by haploinsufficiency and redefine AIOLOS functional domains
AIOLOS, also known as IKZF3, is a transcription factor that is highly expressed in the lymphoid lineage and is critical for lymphocyte differentiation and development. Here, we report on 9 individuals from 3 unrelated families carrying AIOLOS variants Q402* or E82K, which led to AIOLOS haploinsufficiency through different mechanisms of action. Nonsense mutant Q402* displayed abnormal DNA binding, pericentromeric targeting, posttranscriptional modification, and transcriptome regulation. Structurally, the mutant lacked the AIOLOS zinc finger (ZF) 5–6 dimerization domain, but was still able to homodimerize with WT AIOLOS and negatively regulate DNA binding through ZF1, a previously unrecognized function for this domain. Missense mutant E82K showed overall normal AIOLOS functions; however, by affecting a redefined AIOLOS protein stability domain, it also led to haploinsufficiency. Patients with AIOLOS haploinsufficiency showed hypogammaglobulinemia, recurrent infections, autoimmunity, and allergy, but with incomplete clinical penetrance. Altogether, these data redefine the AIOLOS structure–function relationship and expand the spectrum of AIOLOS-associated diseases.
- 1 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (3)
Open AccessDisease-associated AIOLOS variants lead to immune deficiency/dysregulation by haploinsufficiency and redefine AIOLOS functional domains
AIOLOS, also known as IKZF3, is a transcription factor that is highly expressed in the lymphoid lineage and is critical for lymphocyte differentiation and development. Here, we report on 9 individuals from 3 unrelated families carrying AIOLOS variants Q402* or E82K, which led to AIOLOS haploinsufficiency through different mechanisms of action. Nonsense mutant Q402* displayed abnormal DNA binding, pericentromeric targeting, posttranscriptional modification, and transcriptome regulation. Structurally, the mutant lacked the AIOLOS zinc finger (ZF) 5–6 dimerization domain, but was still able to homodimerize with WT AIOLOS and negatively regulate DNA binding through ZF1, a previously unrecognized function for this domain. Missense mutant E82K showed overall normal AIOLOS functions; however, by affecting a redefined AIOLOS protein stability domain, it also led to haploinsufficiency. Patients with AIOLOS haploinsufficiency showed hypogammaglobulinemia, recurrent infections, autoimmunity, and allergy, but with incomplete clinical penetrance. Altogether, these data redefine the AIOLOS structure–function relationship and expand the spectrum of AIOLOS-associated diseases.
- Open Access
- 1 January 2018
- Published by Elsevier in World Allergy Organization Journal
- Vol. 11 (1) , 8
The importance of allergic disease in public health: an iCAALL statement
- 1 January 2018
- Published by Elsevier in World Allergy Organization Journal
- Vol. 11 (1) , 8
Open AccessThe importance of allergic disease in public health: an iCAALL statement
- Top Cited Papers
- 1 April 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (4) , 1099-1110
The microbiome in allergic disease: Current understanding and future opportunities—2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology
- 1 April 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (4) , 1099-1110
Top Cited PapersThe microbiome in allergic disease: Current understanding and future opportunities—2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology
- 1 March 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (3) , 715-723
Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders
- 1 March 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (3) , 715-723
Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders
- 11 February 2016
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 83 (5) , 444-449
Application of Flow Cytometry in the Evaluation of Primary Immunodeficiencies
Primary immunodeficiency disorders (PIDDs) are a heterogeneous group of inherited disorders of the immune system. Currently more than 250 different PIDDs with a known genetic defect have been recognized. The diagnosis of many of these disorders is supported strongly by a wide variety of flow cytometry applications. Flow cytometry offers a rapid and sensitive tool for diagnosis and classification of PIDDs. It is applicable in the initial workup and subsequent management of several primary immunodeficiency diseases. As our understanding of the pathogenesis and management of these diseases increases, the majority of these tests can be easily established in the diagnostic laboratory. Thus, the focus of this article is on the application of flow cytometry in the diagnosis and/or evaluation of PIDDs.
- 11 February 2016
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 83 (5) , 444-449
Application of Flow Cytometry in the Evaluation of Primary Immunodeficiencies
Primary immunodeficiency disorders (PIDDs) are a heterogeneous group of inherited disorders of the immune system. Currently more than 250 different PIDDs with a known genetic defect have been recognized. The diagnosis of many of these disorders is supported strongly by a wide variety of flow cytometry applications. Flow cytometry offers a rapid and sensitive tool for diagnosis and classification of PIDDs. It is applicable in the initial workup and subsequent management of several primary immunodeficiency diseases. As our understanding of the pathogenesis and management of these diseases increases, the majority of these tests can be easily established in the diagnostic laboratory. Thus, the focus of this article is on the application of flow cytometry in the diagnosis and/or evaluation of PIDDs.
- 1 February 2013
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 131 (2) , 622-623.e4
Laboratory evaluation for T-cell dysfunction
- 1 February 2013
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 131 (2) , 622-623.e4
Laboratory evaluation for T-cell dysfunction
- 1 December 2012
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 12 (6) , 609-615
Monogenic defects in lymphocyte apoptosis
The recognition that apoptosis - programmed cell death - is an important mechanism in immune homeostasis has led to the identification of human disorders associated with defects in the critical control mechanism. Patients have been identified with defects affecting the extrinsic apoptotic pathway mediated by the protein receptor FAS which results in the autoimmune lymphoproliferative syndrome and more recently in defects affecting the intrinsic apoptotic pathway mediated by RAS proteins resulting in the RAS-associated autoimmune leukoproliferative disorder. This review summarizes the immunopathogenesis, clinical features and diagnostic approaches to these human disorders. Apoptotic pathways are critical in the maintenance of leukocyte homeostasis, and genetic defects impacting these can result in clinical disease manifested as expansion of selected leukocyte populations, autoimmunity, increased risk for malignancy and in some situations defects in host defense.
- 1 December 2012
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 12 (6) , 609-615
Monogenic defects in lymphocyte apoptosis
The recognition that apoptosis - programmed cell death - is an important mechanism in immune homeostasis has led to the identification of human disorders associated with defects in the critical control mechanism. Patients have been identified with defects affecting the extrinsic apoptotic pathway mediated by the protein receptor FAS which results in the autoimmune lymphoproliferative syndrome and more recently in defects affecting the intrinsic apoptotic pathway mediated by RAS proteins resulting in the RAS-associated autoimmune leukoproliferative disorder. This review summarizes the immunopathogenesis, clinical features and diagnostic approaches to these human disorders. Apoptotic pathways are critical in the maintenance of leukocyte homeostasis, and genetic defects impacting these can result in clinical disease manifested as expansion of selected leukocyte populations, autoimmunity, increased risk for malignancy and in some situations defects in host defense.
- 1 January 2012
- Published by Springer Nature
- p. 1307-1314
Immune Dysregulation Disorders
- 4 August 2010
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 10 (6) , 460-467
Molecular- and Flow Cytometry-based Diagnosis of Primary Immunodeficiency Disorders
Primary immunodeficiencies are an expanding group of genetic disorders resulting in recurrent and/or severe infections, autoimmunity, or autoinflammation. The laboratory plays a critical role in the diagnosis of these conditions given their frequently overlapping signs and symptoms. We discuss here advances in flow cytometry and molecular techniques applied to the study of primary immunodeficiencies.
- 4 August 2010
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 10 (6) , 460-467
Molecular- and Flow Cytometry-based Diagnosis of Primary Immunodeficiency Disorders
Primary immunodeficiencies are an expanding group of genetic disorders resulting in recurrent and/or severe infections, autoimmunity, or autoinflammation. The laboratory plays a critical role in the diagnosis of these conditions given their frequently overlapping signs and symptoms. We discuss here advances in flow cytometry and molecular techniques applied to the study of primary immunodeficiencies.